Every 8-K that Acadia Pharmaceuticals Inc. (ACAD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ACAD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACAD filings page.
ACADIA Pharmaceuticals Inc. reported Phase 2 topline results from the RADIANT program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis. At week 6, once-daily 60 mg remlifanserin had a change from baseline of -12.6 on SAPS-H+D versus -10.4 for placebo (standardized effect size 0.26; p=0.0603). On the key secondary measure, CGI-S-ADP, the changes were -1.3 versus -0.9 (standardized effect size 0.37; nominal p=0.0077). The difference between 60 mg and placebo increased through the six-week treatment period on both measures.
Acadia described safety findings across both doses as favorable, with adverse-event rates similar to placebo, no signal of QT prolongation versus placebo, and no deaths in the remlifanserin treatment arms. The company plans to continue enrolling in two ongoing Phase 3 studies while amending the program, including removing the 30 mg dose arm. Remlifanserin is also being studied in Phase 2 for Lewy body dementia psychosis.
Acadia Pharmaceuticals reported GAAP total revenues of $308 million for the quarter ended June 30, 2026, up 16% from $265 million a year earlier and 17% versus non-GAAP adjusted revenues. NUPLAZID net sales were $183 million, up 9% year-over-year and 10% on a non-GAAP adjusted basis, while DAYBUE net sales reached $125 million, up 30%. Quarterly net income was $32 million, or $0.18 per diluted share, and cash, cash equivalents and investment securities totaled $956 million.
The company raised its 2026 total revenue guidance to $1.24–$1.30 billion, increased DAYBUE sales guidance to $480–$510 million, and lowered expected R&D expenses to $355–$380 million. Acadia highlighted progress for remlifanserin in Alzheimer’s disease psychosis, including FDA Fast Track designation and ongoing RADIANT Phase 2/3 work, and noted a CHMP positive opinion recommending EU marketing authorization for DAYBU in Rett syndrome.
Acadia Pharmaceuticals Inc. reported that stockholders approved an amendment to its 2024 Equity Incentive Plan, increasing the number of common shares authorized for issuance under the plan by 5,209,670. This approval occurred at the company’s 2026 Annual Meeting of Stockholders, following prior approval of the amendment by the board.
At the meeting, three Class I directors were elected, with each nominee receiving over 128 million votes in favor. Stockholders also approved the other proposals presented, with support levels generally above 147 million votes for key items, and the company has filed the amended equity plan as Exhibit 10.1.
Acadia Pharmaceuticals reported first quarter 2026 total revenues of $268 million, up 10% from $244 million a year earlier, driven by neurology drugs NUPLAZID and DAYBUE. GAAP net product sales were $167 million for NUPLAZID, up 5% year-over-year, and $101 million for DAYBUE, up 20% year-over-year, helped by the U.S. launch of the DAYBUE STIX formulation.
Research and development expenses were $77 million, roughly flat versus 2025, while selling, general and administrative expenses rose to $171 million from $126 million as the company invested behind commercial growth. Net income declined to $3.6 million, or $0.02 per diluted share, from $19.0 million, reflecting higher operating costs. Cash, cash equivalents and investment securities totaled $851 million as of March 31, 2026. Acadia reaffirmed its full-year 2026 guidance, including total revenues of $1.22–$1.28 billion, NUPLAZID net product sales of $760–$790 million, DAYBUE net product sales of $460–$490 million, and R&D and SG&A expense ranges. The company also highlighted upcoming Phase 2 topline results for remlifanserin in Alzheimer’s disease psychosis expected between August and October 2026.
Acadia Pharmaceuticals Inc. announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., its Head of Research and Development. Dr. Thompson, who joined the company in 2024, is retiring for personal reasons and will remain in her role during a transitional period until a successor is appointed.
After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to support continuity, including through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer’s disease psychosis and into early Phase 3 execution. Ongoing clinical trials, including Phase 2 studies of remlifanserin in Alzheimer’s disease psychosis and Lewy Body Dementia Psychosis, are continuing as planned, and the company has begun a search for a new Head of Research and Development.
Acadia Pharmaceuticals Inc. appointed Jonathan M. Poole to its board of directors and Audit Committee, effective March 3, 2026, to fill a vacancy as a Class II director with a term running through the 2027 annual meeting.
Under the company’s non-employee director compensation policy, he will receive an annual cash retainer of $50,000 for board service and $12,500 for Audit Committee service, both prorated. He received an initial equity grant valued at $200,000, split equally between stock options and restricted stock units, vesting annually over three years, plus a prorated annual equity grant of $95,300 vesting over approximately one year. Beginning with the 2026 annual meeting, he will be eligible for annual equity grants with a target value of $400,000, also split between options and RSUs.
Acadia Pharmaceuticals reported strong fourth-quarter and full-year 2025 results, with GAAP total revenues of $284 million for the quarter and $1.07 billion for the year, up 9% and 12% year over year.
Non-GAAP adjusted total revenues reached $298 million in the quarter and $1.08 billion for 2025, reflecting faster growth of 16% and 14%. NUPLAZID generated GAAP net sales of $174 million in Q4 and $680 million for the year, while DAYBUE delivered $110 million in Q4 and $391 million for 2025, both growing double digits.
Net income jumped to $274 million in Q4 and $391 million for 2025, helped by a non‑cash income tax benefit of $250 million. Cash, cash equivalents, and investment securities rose to $820 million. For 2026, Acadia guides total revenues of $1.22–$1.28 billion, with continued sales growth expected from NUPLAZID and DAYBUE.
Acadia Pharmaceuticals Inc. reported at the J.P. Morgan Healthcare Conference that it anticipates 2025 net sales will exceed $1 billion, in line with its prior guidance. The company shared this outlook in a corporate slide presentation and has made the slides available in the investors section of its website at ir.acadia.com. The update was furnished in a current report under results of operations and financial condition and accompanying Regulation FD disclosure.
Acadia Pharmaceuticals Inc. furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1.
The information in this report and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference except as specifically stated. The press release is dated November 5, 2025.
Acadia Pharmaceuticals Inc. announced that Daniel B. Soland has resigned from its Board of Directors and from his role as Chair of the Nominating and Corporate Governance Committee, effective October 30, 2025. The company stated that his resignation was not due to any dispute or disagreement regarding the company’s operations, policies, or practices.